COOPERATIVE STUDY OF CANCER CHEMOTHERAPY

癌症化疗的合作研究

• 批准号: 2007148
• 负责人: LAURENCE ELIAS
• 金额: $ 21.35万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 1997-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2007148
• 关键词: acute leukemia; acute myelogenous leukemia; acute nonlymphocytic leukemia; adenocarcinoma; antineoplastics; biomarker; breast neoplasms; chlorambucil; chromosome translocation; cis platinum compound; clinical trials; colony stimulating factor; colorectal neoplasms; combination cancer therapy; combination chemotherapy; cooperative study; cytosine arabinoside; daunorubicin; doxorubicin; flow cytometry; head /neck neoplasm; human subject; human therapy evaluation; interferon alpha; interferon gamma; interleukin 1; interleukin 2; interleukin 4; lymphocytic leukemia; lymphoma; melanoma; melphalan; metastasis; multidrug resistance; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; ovary neoplasms; pancreas neoplasms; polymerase chain reaction; prognosis; prostate neoplasms; renal cell carcinoma; squamous cell carcinoma; surface antigens; tumor necrosis factor alpha; uterus neoplasms

Patients who have cancer will be treated with Phase III protocols of the Southwest Oncology Group in an interdisciplinary approach utilizing surgery, radiotherapy, chemotherapy (which includes variable schedules and combinations of drugs, including both investigational agents and already proven and accepted drugs, either alone or in combination with radiotherapy; these forms of therapy would represent the current most effective drug combinations identified by group studies), and immuno- therapy. Patients who are unresponsive to the above therapy will be managed with new experimental agents, which have been carefully evaluated for dosage and toxicity, and which show suggestive evidence of anti-tumor effect in specific malignancies. These will represent the Phase II protocol studies of the Southwest Oncology Group. Ancillary studies utilizing patient material being evaluated in the above protocols will be coordinated with research activities of other departments in the areas of pathology, immunology, biochemistry, pharmacology, and anatomy through independent grant support. Specifi- cally, the University of New Mexico flow lab will function as one of the referral institutions performing flow cytometry for the Southwest Oncology Group. UNM will also continue to perform cell surface marker analyses on various Southwest Oncology Group leukemia protocols. The University of New Mexico has been a major scientific contributor to the Southwest Oncology Group in the past and this will remain one of the institution's top priorities. In addition, the recruitment of medically underserved populations (specifically Hispanic and American Indian) and women to Southwest Oncology Group studies will continue to be a major commitment of the University of New Mexico.

患有癌症的患者将接受III期方案的治疗， 西南肿瘤学小组采用跨学科方法， 手术、放疗、化疗（包括可变时间表 和药物组合，包括研究药物和 已经被证明和接受的药物，无论是单独或与 放疗;这些形式的治疗将代表目前最 通过分组研究确定的有效药物组合），以及免疫- 疗法 对上述治疗无反应的患者将 使用新的实验药剂进行管理，这些药剂已经过仔细评估 剂量和毒性，并显示抗肿瘤的提示性证据 在特定恶性肿瘤中的作用。 这些将代表第二阶段 西南肿瘤组的研究方案。 使用上述评价的患者材料的辅助研究 协议将与其他研究活动协调 病理学，免疫学，生物化学， 药理学和解剖学通过独立的赠款支持。 具体- 卡利，新墨西哥州大学的流动实验室将作为一个功能， 为西南地区开展流式细胞术的转诊机构 肿瘤组。 UNM还将继续进行细胞表面标记 西南肿瘤组白血病治疗方案的分析 新墨西哥州大学一直是一个主要的科学贡献者， 西南肿瘤组在过去，这将仍然是一个 机构的首要任务。 此外，招聘医务人员， 服务不足的人群（特别是西班牙裔和美洲印第安人）， 西南肿瘤学小组的研究将继续是一个主要的 新墨西哥州大学的承诺。